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Abstract
Background: Mood and anxiety and related disorders (AD) account for a significant proportion of mental health
conditions, with close to 30 % of the population (28.8 %) suffering from an AD at some time in their life, and over
fifteen percent (16.2 %) suffering from a mood disorder. The existing empirical literature leaves a number of
important gaps with respect to our understanding of mood, anxiety and stress related difficulties among pregnant
and postpartum women. The objective of this research is to address these.
Methods: Participants were 660 English-speaking pregnant women. Participants for the portion of the research
estimating the prevalence/incidence of perinatal mood disorders and AD (N = 347) were recruited proportionally
from a geographically defined area. All participants were recruited via prenatal clinic visits at hospitals, physician
offices and midwifery clinics, and via community outreach at events and through word of mouth. Recruitment took
place between November 9, 2007 and November 12, 2010. Participants were administered questionnaires prenatally
at two time points (approximately 24 and 33 weeks gestation) and again at 4–6 weeks’ postpartum and 6-months
postpartum. Prevalence/incidence study participants who screened above cut-off on one or more of the 4–6 week
mood and anxiety questionnaires were also administered a diagnostic interview for mood disorders and AD at
approximately 8–12 weeks postpartum.
Discussion: This research addresses a number of gaps in our understanding of mood, anxiety and stress among
pregnant and postpartum women. Specifically, gaps in our knowledge regarding the prevalence and incidence of
(a) AD and mood disorders, and (b) anxiety and stress among women experiencing a medically high-risk
pregnancy, interest in stress management training in pregnancy, mental health treatment barriers and access and
screening for anxiety among pregnant and postpartum women are addressed. The findings from this series of
studies have the potential to improve screening, assessment and treatment of mood and anxiety problems suffered
by pregnant and postpartum women.
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Background
Mood and anxiety and their related disorders (AD) account
for a significant proportion of mental health conditions,
with close to thirty percent of the population (28.8 %) suf-
fering from an AD at some time in their life, and over fif-
teen percent of the population (16.2 %) suffering from a
mood disorder [1]. Half of all depressed patients also report
symptoms meeting criteria for one or more AD [2]. De-
pression is the leading cause of disease-related disability
among women [1], and women are also 1.6–1.7 times more
likely to suffer from depression and/or AD during their life-
time than are men [3]. The perinatal period is of particular
importance as maternal mood and anxiety difficulties are
associated with adverse pregnancy outcomes, compro-
mised parenting, impaired affect and behaviour regula-
tion, and insecure attachment in offspring [3–9].
Anxiety during pregnancy is associated with adverse
pregnancy outcomes such as miscarriage, preeclampsia,
preterm delivery, and low birth weight [3, 10]. Further,
children of highly anxious mothers have twice the risk
for ADHD [11, 12]. Prenatal anxiety has been identified
as a strong predictor of postpartum depression, even
after controlling for prenatal depression levels [13–15].
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In published reports of the prevalence and/or inci-
dence of AD in pregnancy and/or the postpartum in
which samples are either representative or unselected,
and assessments are based on gold standard assessment
methods (i.e., diagnostic interviewing), the prenatal
prevalence of AD ranges from 13 to 21 %, with the post-
partum prevalence ranging from 11 to 17 % [16–19].
Postpartum incidence ranged from 2.2 to 8.8 %. None of
these studies have included the full spectrum of the AD
[18, 19]. A key objective of this research is to estimate
the prevalence/incidence of the full spectrum of postpar-
tum AD. If maternal AD are as common as they appear
to be, then these disorders have serious negative conse-
quences for a significant proportion of infants/children.
Depression and anxiety in pregnancy represent two of
the strongest risk factors for postpartum depression
[13, 20–22]. Similarly, postpartum depression is associ-
ated with significant emotional and marital distress as
well as compromised physical and social functioning
[23, 24]. Although a number of large-scale, high quality
studies have assessed the prevalence of pre and postna-
tal depression (i.e., an episode of major depression),
using gold standard assessment methods (i.e., diagnos-
tic interviewing), to our knowledge, these estimates are
based exclusively on episodic criteria or symptom se-
verity; they are not based on the full diagnostic criteria
for major depressive disorder [25, 26]. Consequently, it
is likely that bipolar conditions contribute to the preva-
lence of postpartum depression. This possibility, to our
knowledge, remains uninvestigated, and represents one
of the objectives of the current research.
Screening for depression among postpartum women is
routine in many places [27, 28]. The Edinburgh Postnatal
Depression Scale (EPDS) is the most commonly used self-
report instrument for the assessment of postpartum de-
pression [29, 30]. Although the EPDS does contain items
specific to anxiety, it is unknown whether the EPDS may
be sufficient to detect the majority of women suffering
from an AD [28, 31]. As a part of this study we have gath-
ered data to determine if the current EPDS screening for
depression is sufficient to detect AD also, or if there is a
need for additional screening for anxiety.
Obstetrical complications, by definition, imply a threat
to the health and well-being of the mother, her develop-
ing infant, or both [32, 33]. Over 20 % of all pregnancies
involve obstetrical risks and account for up to 8000
births per year in British Columbia (BC), Canada alone
[34]. While pregnancy can be a source of stress and anx-
iety for women who are experiencing normal, low-risk
pregnancy, it is likely much more stressful and anxiety
producing for women experiencing a pregnancy fraught
with difficulties [35]. It is therefore likely that the preva-
lence of stress and AD among women experiencing a
medically high-risk pregnancy may be even higher.
Understanding the extent of stress and anxiety among
high-risk obstetrical patients would provide extremely
important information regarding the mental health
needs of this group of vulnerable women. Despite the
serious nature of medically high-risk pregnancies, which
contribute to excess maternal and perinatal morbidity
and mortality and corner a disproportionate among of
health services expenditures, to date there have been no
systematic studies of the prevalence of perinatal stress
and anxiety among these women. This research aims to
address this gap.
Objectives
This research was multifaceted and involved several in-
terconnected projects encompassing four broad areas of
research: (a) perinatal AD, (b) perinatal mood disorders,
(c) perinatal mental health treatment access, and (d)
medically high risk pregnancy. The specific objectives
within each of these areas are outlined below:
Perinatal AD.
1. Primary objectives: To determine:
a. the prevalence of maternal AD at 6–8 weeks
postpartum, and
b. if additional screening beyond the EPDS is
required in order to ensure adequate detection of
AD among postpartum women.
2. Secondary objectives: To determine:
i. the level of comorbidity of mood and AD at 6–8
weeks postpartum,
ii. the temporal sequencing of AD and mood
disorders during pregnancy and at 6–8 weeks
postpartum, and
iii. the course of anxiety symptoms from pregnancy
to 6–8 weeks postpartum.
Perinatal mood disorders.
1. Primary objectives: To assess:
a. the contribution of the following to the
prediction of depression (i.e., symptom severity
and diagnostic status) at 8-weeks postpartum:
i. maternal, prenatal symptoms of the 6
primary AD (i.e., social anxiety, specific
phobias, obsessive-compulsive disorder,
posttraumatic stress disorder, panic disorder
and agoraphobia); and
ii. maternal, prenatal symptoms of pregnancy
specific stress.
b. the distribution of mood disorders (i.e., major
depressive disorder, minor depressive disorder
and bipolar disorders) among postpartum women
diagnosed with an episode of major depression.
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2. Secondary objectives: To determine:
a. the prevalence of maternal postpartum
depression at 6–8 weeks postpartum;
b. if the current, Province wide, self-report based
screening for postpartum depression is sufficient
to adequately detect AD among postpartum
women, or if supplementary anxiety specific
screening is needed; and
c. the course of mood symptoms from pregnancy to
6-months postpartum.
Perinatal mental health treatment access.
Assess 6-month postpartum mental healthcare access,
use and cost among women diagnosed with mood disor-
ders at 6–8 weeks postpartum.
Medically high risk pregnancy.
1. Primary objective: To assess the prevalence, nature
and severity of anxiety and stress among women
experiencing a medically high-risk pregnancy.
2. Secondary objectives:
a. To compare pre and postnatal levels of anxiety
and stress among women experiencing a
medically high-risk pregnancy with those of
women experiencing a normal low-risk pregnancy;
b. To estimate the prevalence of persistent
postpartum anxiety and stress among women who
experienced a medically high-risk pregnancy; and
c. To assess the acceptability of and preference for
prenatal stress management training among






Ethical approval for the research was granted by the
University of British Columbia/Children’s and Women’s
Health Centre of British Columbia Research Ethics
Board (UBC C&W REB). Consent for the completion of
questionnaire packages was obtained from participants
via online and/or mailed forms. A second consent was
completed by all interview participants, for their partici-
pation in the interview portion of the research.
Inclusion/Exclusion criteria
Study participants were classified as either: (a) those
who met the inclusion/exclusion criteria for the full
sample, and (b) those who met the more restrictive in-
clusion/exclusion criteria for the mood and AD preva-
lence sample. The inclusion/exclusion criteria for the
prevalence sample were more restrictive as it was neces-
sary to ensure representativeness of this portion of our
sample of birthing women.
Full sample
All pregnant women fluent in English were eligible to
participate.
Prevalence sample
Prospective participants were eligible to participate if
they lived in the City of Vancouver, Canada at the time
of recruitment, were pregnant, and spoke English flu-
ently. The City of Vancouver was selected as the geo-
graphical boundary for the research.
Recruitment
Pregnant women were recruited via prenatal clinic visits,
physician offices and midwifery clinics at BC Women’s
Hospital, St Paul’s Hospital and Burnaby Hospital, through
community outreach at events and through word of
mouth. Formal arrangements for recruitment were made
with the appropriate individuals at each of the above-
mentioned locations. Recruitment at these sites was pri-
marily carried out via direct-approach (i.e., approaching
women as they waited for their appointments). The re-
mainder were recruited passively through the use of post-
ers and pamphlets. Recruitment took place between
November 9, 2007 and November 12, 2010. A total of 668
women consented to participate.
Representativeness (Prevalence Sample)
Based on 2003/2004 statistics, approximately 6000 ba-
bies are born to Vancouver residents each year (British
Columbia Reproductive Care Program, 2004). Of these,
98 % of births by Vancouver residents take place at BC
Women’s Hospital (73 %), Saint Paul’s Hospital (19 %),
Burnaby Hospital (4 %), or at home (2 %). To maximize
the representativeness of our sample, we recruited pro-
portionally from each of the recruitment sites. Addition-
ally, data weighting will be used during analysis, where
appropriate, to ensure that our collected data are repre-
sentative of the sites of birth of the general population
of birthing women in Vancouver.
Participants
Prevalence sample
There are 347 women in the prevalence portion of the
research. Of these, 152 were eligible for interview based
on their questionnaire responses. Of the 152 potential
interview participants, 37 either declined to be inter-
viewed (n = 7), were unresponsive to our attempts to
schedule an interview (n = 9), or were not invited due to
administrative error (n = 21). The final sample com-
prised 310 participants.
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Of these, 76.3 % gave birth at BC Women’s Hospital,
16.3 % at Saint Paul’s Hospital, and 1.8 % at home. The
remainder (5.7 %) gave birth elsewhere. On average,
women were 27.3 weeks pregnant (SD = 8.5) at the time
of enrollment. The vast majority were married (79.4 %)
or living with a partner (16.6 %). The remainder were
single (3.1 %), divorced (0.3 %), or separated (0.6 %). The
majority of participants were Caucasian (72.4 %) or
Asian (18.5 %). The remainder were First Nations Canadians,
Hispanic, or Middle Eastern (3.4 %), or did not provide
data regarding race/ethnicity (5.7 %). For 64.7 % of the
sample, they were expecting their first child. Most were
singleton pregnancies (94.3 %), and several were twin
pregnancies (4.2 %).
Full sample
There are a total of 660 participants in the full study
sample. Participants gave birth at BC Women’s Hospital
(70.5 %), Saint Paul’s Hospital (9.3 %), home (3.0 %),
Burnaby General Hospital (1.5 %), and other (11.7 %).
The vast majority were married (80.3 %) or living with a
partner (16.6 %). The remainder were single (5.1 %),
divorced (0.3 %), or separated (0.3 %). The majority of
participants were White/European (70.3 %) or Asian
(22.6 %). The remainder were First Nations Canadians,
Black, Hispanic, Middle Eastern, or Caribbean (5.3 %),
or of mixed racial background. Over half (57.3 %) of the
sample was expecting their first child. There were 594
singleton pregnancies, 34 twin pregnancies, and one set
of triplets.
Sample size
Our final prevalence sample size of 310 women will per-
mit us to determine the prevalence of AD (assuming the
prevalence to be approximately 15 %), with a 95 % confi-
dence interval, to within ±3.97 %. Assuming the preva-
lence of perinatal depression to be approximately 6 %,
the 95 % confidence interval would be accurate to within
±2.64 %.
Screening
Women invited to participate in the study, were asked to
complete up to four sets of screening questionnaires for
anxiety and depression across pregnancy and the first 6-
months postpartum. Most women entered the study be-
tween 30 and 32 weeks gestation, completing the first
screening package at this time. Women who were re-
cruited at or before 24 weeks gestation were administered
an additional early prenatal questionnaire package. At 40-
weeks’ gestation, participants were mailed the same
screening package and asked to complete and return it be-
tween 4 and 6 weeks postpartum. Women who were resi-
dents of Vancouver at the time of recruitment and scored
above predetermined cut-offs on any of the mood and
anxiety measures, completed at 4–6 weeks postpartum,
were telephoned and invited to participate in the interview
portion of the study.
Interviews
Project interviewers conducted diagnostic assessments
of all participants who (a) scored above cut-off on any of
the postpartum screening measures, (b) were resident of
the City of Vancouver at the time of study enrolment
and (c) consented to participate in the interview portion
of the study. In total 123 of the 310 women in the preva-
lence sample were interviewed. Diagnostic assessments
took place between 6 and 8 weeks postpartum. Women
were offered the choice of coming to BC Women’s Hospital
for their interview, or having the interview conducted
in their (the participant’s) home. The vast majority (i.e.,
> 90 %) elected to have the interview conducted in their
home. At the time of the diagnostic assessment, women
with symptoms meeting criteria for any mood or AD were
provided with appropriate mental health referrals.
Follow-up assessment
At 6-months postpartum, all participants were sent
follow-up questionnaires to assess:
i. Current status of mood and anxiety symptoms.
ii. Mental health care received since the birth of their baby.
iii. Appropriateness of the care based on the 4-week
postnatal diagnostic assessment.
iv. Out of pocket cost for mental health care.
v. Accessibility of mental healthcare received.
Assessment tools
Demographic and reproductive measures
Included in the initial questionnaire package were demo-
graphic questions including age, income, education, and
marital status. Information about past and current medical
and reproductive history was also obtained. In later ques-
tionnaire packages participants were asked for information
about changes in health status as well as labour and deliv-
ery experiences. These questions included a mixture of
multiple choice and open-ended questions as needed.
Self-report measures
The following measures were used to assess for symptoms
of all six AD and for depression. Women completed each
of these screening tools at each study time point and
returned them by mail to the investigators. These mea-
sures have been selected because they are psychometric-
ally sound and possess good sensitivity and specificity.
Generalized anxiety disorder 7-item scale (GAD-7)
[36] the GAD-7 s a 7-item self-report measure designed
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to assess for generalized anxiety disorder (GAD) [36].
Items are rated on a 0–3, Likert-type scale. Higher scores
are indicative of higher levels of symptoms of GAD. The
GAD-7 has been found to demonstrate good reliability as
well as convergent (with worry, anxiety, low mood and
stress), criterion, construct, factorial, and procedural valid-
ity [36, 37]. The GAD-7 is also sensitive to change over
time [37]. Compared with the EPDS, the GAD-7 was
more reliable and valid in identifying GAD among preg-
nant. The optimal cut point for optimizing sensitivity and
specificity has been found to be 10 [36]. Consequently, we
selected a cut score of 10 for this study, representing a
sensitivity of 89 % and a specificity of 82 %.
Obsessive compulsive inventory – revised (OCI-R;
Foa, et al., 2002) [38] the OCI-R is an 18-item self-
report measure of symptoms of OCD. Items are scored
on a 5-point, Likert-type scale from 0 to 4. The factor
structure of the OCI-R indicates a 6-factor model with
3-items in each factor [38]. These factors represent the
following content domains: Washing, Checking, Obses-
sing, Hoarding, Ordering, and Neutralizing. The psycho-
metric properties of the OCI-R are excellent [38–41].
When used as a screening tool to detect OCD, the OCI-
R obsessing scale shows higher levels of sensitivity
(74 %) and specificity (76 %) compared with the full
OCI-R (66 % for sensitivity and 63 % for specificity) [38].
Consequently, we have used the OCI-R obsessing sub-
scale as our measure of OCD. The OCI-R obsessing sub-
scale shows good internal consistency with coefficient
alphas ranging from 0.77 to 0.89 [38, 39]. We used a
cut-off score of 4 on the obsessing subscale. This repre-
sents a sensitivity of 74.4 % and a specificity of 76.1 %.
Mini social phobia inventory (Mini-SPIN) [42] the
Mini-SPIN is a brief, 3-item measure derived from the full
scale Social Phobia Inventory (SPIN) [43]. Mini-SPIN
items were selected from the full scale SPIN as follows.
The authors selected the SPIN items which best discrimi-
nated between those with generalized social anxiety dis-
order and controls. To do this, the three items with the
greatest difference in mean score between those with gen-
eralized social anxiety and controls were selected. Items
are scored on a 0 (not at all) to 5 (extremely) Likert-type
scale. A cut-score of 6 on the Mini-SPIN has been found
to represents good sensitivity (88.7 and 93.8 %) and speci-
ficity (89.9 and 63.6 %) [42, 44]. The Mini-SPIN has been
found to demonstrate strong internal consistency reliabil-
ity, as well as convergent and discriminant validity [44].
Panic disorder self-report (PDSR) [45] the PDSR is a
hierarchical questionnaire designed to screen for panic
disorder, modeled following the panic disorder module
of the Anxiety Disorder Interview Schedule (ADIS-IV)
[46]. The PDSR begins with questions key to a diagnosis
of panic disorder. Only if these initial questions are an-
swered in the affirmative, are the remaining questions ad-
ministered. The initial four items assess the recurrent and
unexpected nature of panic attacks, followed by three
items assessing worry that attacks will recur, and changes
in behaviour in response to the panic attacks. The final 12
items assess symptoms of the attacks and their interfer-
ence with life. A score of 8.75 has been found to optimize
sensitivity and specificity and was therefore selected for
this research [45]. At 8.75, the PDSR demonstrates a sen-
sitivity of 89 % and a specificity of 100 %. The PDSR has
been found to have excellent test-retest reliability, and
convergent and discriminant validity [45].
Mobility inventory for agoraphobia (MI) [47] the MI
is a 27-item self-report inventory of avoidance behav-
iours and panic attacks in agoraphobia. The measure as-
sesses agoraphobic avoidance on two scales, one when
the person is alone and the other when accompanied.
Items are scored on a 1 (rarely avoids) to 5 (always
avoids) Likert-type scale. Test-retest reliability has been
shown to be .75-.86 for the accompanied subscale, and
.75-.90 for the alone subscale [48]. A number of cutoff
scores have been suggested for the MI, however we
chose an average of alone and accompanied score of 1.5 as
the cutoff. This score has been shown to have a sensitivity
of 78 % and specificity between 76 and 85 %. When using
the avoidance alone scale with a cutoff score of 1.5 the
sensitivity is 91 % and specificity is 67 % [49].
Specific phobia questionnaire (SPQ) [50, 51] the SPQ
(Fairbrother & Antony, 2011) is a 43-item, self-report
measure of specific phobias. Each item assesses a spe-
cific fear (e.g., dogs, elevators, driving in new places) and
includes a rating for fear and for interference. The fear
and interference ratings are scored on a 0 (none) to 4
(extreme), Likert-type scale. The measure has been ad-
ministered in the current study as well as to a clinical
sample of over 700 individuals diagnosed with one or
more AD, and a student sample of approximately 200.
To date, the SPQ fear of dogs item has been found to cor-
relate well with the Dog Phobia Questionnaire (r = 0.73 for
fear and 0.60 for interference) [50]. Further psychometric
analysis of the SPQ is currently underway. In the current
study, we used a cut-off score of 6 or greater (combined
fear and interference ratings) on one or more SPQ items.
PTSD checklist (PCL) [52] the PCL is 17-item self-
report measure to assess symptoms of posttraumatic
stress disorder (PTSD). Items are rated on a 1 (not at
all) to 5 (extremely) Likert-type scale. Total possible
scores range from 17 to 85. The PCL has been found to
have good internal consistency, test-retest reliability, and
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convergent validity [53]. For this study, we selected a
cutoff score of 44, as this maximizes sensitivity (94 %)
and specificity (86 %). This is compared to a cutoff score
of 50 which has a sensitivity and specificity of 78 and
86 %, respectively [52].
Edinburgh postnatal depression scale (EPDS) [29]
The EPDS is a 10-item self-report measure screening
tool for postnatal depression. The sensitivity and specifi-
city of the EPDS are in acceptable ranges (65–100 %,
and 49–100 %, respectively) [54]. Higher sensitivity rela-
tive to specificity is appropriate for a screening instru-
ment. The EPDS is the most widely used screening tool
for postpartum depression [55].
Diagnostic instrument
The Structured Clinical Interview for DSM-IV (SCID-IV)
[56] is a well-validated structured diagnostic interview
designed for the assessment of a wide range of psychi-
atric problems including all the mood and AD. The




iv. History of psychiatric problems.
v. History of mental health service utilization (e.g.,
psychiatric hospitalizations, pharmacological and
psychosocial interventions for psychological
problems and diagnoses previously assigned).
Analysis
Data will be analysed using SPSS Version 22.
Perinatal AD
We will provide 95 % confidence intervals for all preva-
lence/incidence estimates of maternal perinatal anxiety
and mood disorders. Z-tests will be used to compare the
sensitivity of depression screening alone in detecting
cases of AD, compared to the sensitivity of a combin-
ation of depression and anxiety screening tools. Informa-
tion about the level of mood and AD comorbidity, and
the timing of disorder onset will be presented descrip-
tively. We will use one-way repeated measures analysis
of variance to examine changes in severity of symptoms
of AD from pregnancy to 6 months postpartum.
Perinatal mood disorders
Multiple linear regression will be used to assess the
unique contribution of symptoms of the six primary AD
and pregnancy-specific stress to the prediction of post-
partum depression. Established risk factors for postpar-
tum depression will be entered as covariates in the first
block. Mood disorder prevalence/incidence estimates
will be presented via 95 % confidence intervals based on
diagnostic interview data. We will use one-way repeated
measures analysis of variance to examine changes in se-
verity of symptoms of depression from pregnancy
through to 6-months postpartum.
Perinatal mental health treatment access
Information about participants’ postpartum use of men-
tal health services, difficulties in access, the match be-
tween their diagnosis and the health care they received,
and the out-of-pocket cost of these services will be pre-
sented descriptively.
Medically high risk pregnancy
Ninety-five percent (95 %) confidence intervals will be
presented for all group means and prevalence estimates.
Between-group comparisons based on continuous ques-
tionnaire data will be analyzed using one way ANOVA.
Between group comparisons of the prevalence of AD
stratified by maternal risk will be analyzed using a chi-
squared test of independence. Interest in stress man-
agement training provided during pregnancy will be
presented descriptively, and compared across risks
groups using one way ANOVA.
Current status
Data collection for the study is complete. The data set
has been cleaned, and a substantial portion of the data
analysis has been completed. Manuscript preparation is
currently underway.
Discussion
Substantial empirical, clinical and policy-directed atten-
tion has been given to perinatal depression. In contrast,
significantly less attention has been given to perinatal
AD [15]. This is surprising, particularly in light of the
fact that AD are likely more common among pregnant
and postpartum women than is depression [16]. Despite
the attention given to perianal depression, little of this
work has investigated the underlying diagnosis of suf-
ferers (i.e., whether depression occurs in the context of a
major depressive disorder, a bipolar disorder, or other
mood disorder). The overarching goal of this series of
interconnected studies is to increase our understanding
of the scope and nature of perinatal mood and anxiety
and disorders.
This research includes the first comprehensive (i.e.,
encompassing all of the AD) study of maternal perinatal
AD, using gold standard assessment procedures, carried
out to date. This will also be the first report of a system-
atic study of the prevalence and course of perinatal
stress and anxiety among women experiencing a medic-
ally high-risk pregnancy. Although significant attention
has been given to understanding of the causes and
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consequences of postpartum depression, a number of
significant knowledge gaps remain. One area of particu-
lar importance is that of the relationship between peri-
natal depression and anxiety. Although we now know
that prenatal anxiety and the presence of a prenatal AD
significantly increase the risk of postpartum depression,
the specific contribution of individual domains of anx-
iety has yet to be investigated. This represents one of the
key objectives of the current research. A further
neglected area is that of the role of bipolar conditions in
postpartum depression. To our knowledge, investiga-
tions of postpartum disorder prevalence have yet to as-
sess the frequency with which postpartum depression
occurs in the context of an underlying bipolar disorder.
Our immediate goal is to improve our knowledge in
these two key areas. Finally, we are also assessing the
utility of the EPDS as a stand-alone screening tool for
perinatal AD.
In summary:
1. We will estimate the prevalence and incidence of
AD among pregnant and postpartum women. This
information will (a) make it possible to decide
where to direct treatment efforts for this population
and (b) provide necessary data for a large-scale
epidemiological study of perinatal AD incidence/
prevalence.
2. We will estimate the prevalence of anxiety and
stress among women experiencing a medically
high-risk pregnancy. This research will provide
critical information regarding the mental health
needs of high-risk obstetrical patients, information
which will guide the development and implementation
of prevention and treatment programs for this group
of vulnerable women.
We will also assess the level of interest of these
women in receiving stress management training in
pregnancy and the preferred delivery format for this
intervention (i.e., in person, via audio or visual
materials, or workbook). Should the level of interest
merit it, we will proceed to the development of a
stress management treatment module for delivery to
this population of women.
3. Among women who are diagnosed with a mental
health condition in pregnancy and or the
postpartum we assess whether they access mental
health services for their condition(s), difficulties in
access, out of pocket costs and the degree to which
the treatment accessed represents an evidence-based
approach to their difficulties. Cognitive behaviour
therapy frequently represents the treatment of
choice for many of the AD and depression. Sadly,
this approach to treatment is often difficult to
access, or is very costly [57]. We are interested in
learning of the challenges women face when seeking
treatment for perinatal mood and anxiety difficulties
(e.g., difficulty locating services, costs associated with
the services), and the frequency with which women
receive treatment which is recognized as an
evidence-based approach to their difficulties. What
we learn from this research has the potential to
impact healthcare funding decisions.
4. Data collected in this study will provide important
information regarding the distribution of mood
disorders (e.g., major depressive disorder, bipolar
disorders) among women who have experienced an
episode of perinatal depression, as well as provide
information about risk factors for postpartum
depression; this information which will contribute to
the development and implementation of prevention
and treatment programs for perinatal women.
5. Our findings will also indicate the number of cases
of maternal AD detected using the EPDS compared
to the number detected using additional self-report
measures of anxiety. This information will allow us
to determine if additional screening, beyond the EPDS,
is needed in order to adequately detect maternal
postpartum AD.
Limitations
While this study aims to fill the gaps left by other re-
search in the field we acknowledge that this research
also suffers from some of the same limitation as previous
work. Specifically, although we were successful in
recruiting proportionally within the defined geographic
area for the prevalence portion of the research, and our
initial recruitment was above our target, the study expe-
rienced a higher loss to follow-up than anticipated and
concluded with a smaller than ideal sample size for some
aspects of the project (e.g., prevalence estimates for indi-
vidual AD). Further, participants were largely self-
selected and therefore our sample is not likely to be fully
representative of the population from which it is drawn.
With respect to the prevalence sample, proportional re-
cruitment and data weighting were used to mitigate dif-
ferences between the population and the sample.
Because diagnostic interviews were conducted in the
postpartum only, the data for the prevalence/incidence
of mood and AD in pregnancy is based on participant
retrospective self-report and may therefore be less reli-
able than the postpartum estimates. For the prevalence/
incidence portion of the research, only those women
who screened above cut-off on self-report measures of
depressed mood and anxiety were invited to be inter-
viewed makes it likely that some cases of anxiety and/
or depression were missed. Consequently, prevalence/
incidence estimates for mood and anxiety and related
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conditions are likely an underestimate of actual popula-
tion rates.
It is also important to note that this study was con-
ducted prior to the publication of the DSM-5 and there-
fore uses definitions and criteria from the DSM-IV
which may lead to differences in comparing with future
studies.
Conclusions
The findings from this series of studies has the potential
to add significantly to our understanding of maternal
perinatal mood and AD, stress and anxiety among
women experiencing a medically high risk pregnancy, as
well as treatment preferences and barriers to access
among pregnant and postpartum women. The aim is to
translate our findings into improved screening, assess-
ment and treatment of mood and anxiety problems suf-
fered by pregnant and postpartum women.
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